2025 United Kingdom Anti-Obesity Drugs Market Revenue Opportunities Report
Description
The 2025 United Kingdom Anti-Obesity Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Obesity Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the UK anti-obesity drugs market are Novo Nordisk, GlaxoSmithKline (GSK), Eli Lilly, and Roche. Novo Nordisk leads with a strong portfolio focused on GLP-1 receptor agonists such as semaglutide (Wegovy), which has received regulatory approval for weight management and dominates the market globally and in the UK. GSK offers over-the-counter anti-obesity medication like Alli and maintains a notable presence. Eli Lilly is rapidly gaining market share with innovative drugs like tirzepatide and oral candidates such as orforglipron, which show promising efficacy and convenience. Roche is also involved in the obesity treatment space, contributing to the broad pharmaceutical effort in the region.
In the UK, these companies are supported by increasing investments and regulatory approvals aimed at addressing the obesity epidemic. Access to GLP-1 drugs like semaglutide and tirzepatide is growing, although mostly through specialist NHS clinics with limited capacity. The private sector is also flourishing, expanding access despite high costs, showing significant demand for effective anti-obesity treatments. These firms focus heavily on research and development, aiming to advance combination therapies and oral formulations to improve outcomes and patient adherence, positioning themselves competitively in a market projected to exceed USD 26 billion by 2035.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Obesity Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the UK anti-obesity drugs market are Novo Nordisk, GlaxoSmithKline (GSK), Eli Lilly, and Roche. Novo Nordisk leads with a strong portfolio focused on GLP-1 receptor agonists such as semaglutide (Wegovy), which has received regulatory approval for weight management and dominates the market globally and in the UK. GSK offers over-the-counter anti-obesity medication like Alli and maintains a notable presence. Eli Lilly is rapidly gaining market share with innovative drugs like tirzepatide and oral candidates such as orforglipron, which show promising efficacy and convenience. Roche is also involved in the obesity treatment space, contributing to the broad pharmaceutical effort in the region.
In the UK, these companies are supported by increasing investments and regulatory approvals aimed at addressing the obesity epidemic. Access to GLP-1 drugs like semaglutide and tirzepatide is growing, although mostly through specialist NHS clinics with limited capacity. The private sector is also flourishing, expanding access despite high costs, showing significant demand for effective anti-obesity treatments. These firms focus heavily on research and development, aiming to advance combination therapies and oral formulations to improve outcomes and patient adherence, positioning themselves competitively in a market projected to exceed USD 26 billion by 2035.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
